Clinical trials: Cirrhosis Portal
End-Stage Liver DIsease
Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues.
- Trial name
- NCT06242405
- Testing
- umbilical cord-mesenchymal stem cells
- Where
- China
- Volunteers
- 92 people
- Sponsor
- General Hospital of Shenyang Military Region
Esophageal Varices, Bleeding
Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding.
In the last years, important advances have been done in the treatment and prevention of esophageal variceal bleeding. Experts agree that the combination of pharmacological and endoscopic therapy should be the first line therapy…
- Conditions
- Esophageal Varices, Bleeding, Cirrhosis
- Trial name
- NCT01242280
- Testing
- Stent, Tamponade
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatitis C, Cirrhosis
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.
- Conditions
- Hepatitis C, Cirrhosis, Fibrosis
- Trial name
- NCT00252642
- Testing
- Peginterferon Alpha-2a
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Virginia Commonwealth University
Minimal Hepatic Encephalopathy
Study of Rifaximin in Minimal Hepatic Encephalopathy
Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.
- Trial name
- NCT01069133
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Esophageal Neoplasms, Cirrhosis
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors.
- Conditions
- Esophageal Neoplasms, Cirrhosis, Portal Hypertension
- Trial name
- NCT04994548
- Testing
- Endosocpic resection of early esophageal tumor
- Volunteers
- 112 people
- Sponsor
- Central Hospital, Nancy, France
Cirrhosis, Ascites Hepatic
Using Bedside Ultrasound to Understand Fluid Management in Patients With Chronic Liver Disease
The goal of this observational study is to see if repeated bedside ultrasound measurements of the lungs and abdomen as well as a blood vessel in the neck can be done in patients with advanced liver disease and ascites (fluid in…
- Conditions
- Cirrhosis, Ascites Hepatic, Fluid Balance
- Trial name
- POCUS-C (NCT07810855)
- Testing
- Ultrasound measurement, Blood draw for the laboratory assessment
- Volunteers
- 100 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Coagulation Disorder, Cirrhosis, Liver
ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension
Hemostasis-related disorders are common in cirrhosis and portal hypertension. However, it is not known whether the net effect of changes in hemostasis in the sense of predisposition to hemorrhagic or thrombotic state.
- Trial name
- NCT04267406
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Portal Hypertension
A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)
Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients with cirrhosis.
- Trial name
- NCT05052892
- Testing
- Hepatic venous pressure gradient
- Where
- 3 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Liver Cirrhosis
To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis.
The study will be conducted on patients attending /admitted to Department of Hepatology from April 2017 to December 2018 at ILBS, New Delhi .
- Trial name
- NCT03161106
- Testing
- Nutrition, Lactulose, Diet
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Esophageal Varices
Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding
Patients with scarring of the liver (cirrhosis) and portal hypertension (elevated blood pressure in the liver vasculature) can develop esophageal varices (dilated veins). These have an increased risk of bleeding each year.
- Trial name
- NCT00409084
- Testing
- endoscopic variceal band ligation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
Liver Cirrhosis, End Stage Liver Disease
Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis
HBV related Liver disease is a common medical problem in China. An estimated 7.18% of the Chinese (about 93 million) is infected with hepatitis B, and most of the HBV- related hepatitis can developed into liver cirrhosis.
- Trial name
- NCT01724697
- Testing
- BMSC transplantation, conventional treatment & antivrial treatment
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Air Force Military Medical University, China
Hepatic Encephalopathy, Cirrhosis, Liver
Oral Fecal Transplant in Cirrhosis
To evaluate the safety and tolerability of oral fecal transplant in patients with cirrhosis and hepatic encephalopathy
- Trial name
- NCT03152188
- Testing
- FMT
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Portal Hypertension Related to Cirrhosis, Ascites
Development and Validation of a TIPS Prognostic Model
This multicenter, prospective observational study aims to learn whether a prediction model using routine clinical data, imaging findings (including spleen stiffness measurement), and circulating biomarkers can predict stent…
- Conditions
- Portal Hypertension Related to Cirrhosis, Ascites, Esophageal Variceal Bleeding
- Trial name
- C-SIPS (NCT07909850)
- Volunteers
- 1,490 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Systemic Inflammatory Markers, Portal Vein Thrombosis
A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis
Immunothrombosis has recently been used to describe the responses/mechanisms in thrombosis. Systemic inflammatory markers are prognostic markers for a variety of thrombotic conditions; however, their potential value in predicting…
- Trial name
- NCT05541562
- Testing
- clinical laboratory tests, and imaging characteristics
- Where
- China
- Volunteers
- 478 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Cirrhosis, Liver Disease Chronic
Inferior Vena Cava Pressure as Alternative to Hepatic Venous Pressure for EUS-guided Portal Pressure Gradient Measurement
This study investigates a new, simplified approach to measuring blood pressure within the liver (portal hypertension) using Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement (EUS-PPG).
- Conditions
- Cirrhosis, Liver Disease Chronic, Portal Hypertension
- Trial name
- EUS-VEIN (NCT07703540)
- Testing
- HVP-PPG and IVCP-PPG
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Muenster
Hepatic Cirrhosis, Ascites
Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.
- Trial name
- NCT01359462
- Testing
- tolvaptan
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Otsuka Beijing Research Institute
Iron Deficiency Anemia, Chronic Liver Failure
Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease.
- Trial name
- NCT04335058
- Testing
- Lactoferrin + Iron Supplement, Iron Supplement
- Where
- India
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Portal Vein Thrombosis, Liver Cirrhosis
TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
portal vein thrombosis may be a negative prognostic marker of variceal bleeding in liver cirrhosis. Compared with conventional endoscopic and pharmacological therapy, transjugular intrahepatic portosystemic shunt may further…
- Trial name
- NCT02485184
- Testing
- Transjugular intrahepatic portosystemic shunt, Non-selective beta blockers, Endoscopic therapy
- Where
- 8 sites in China
- Volunteers
- 120 people
- Sponsor
- Air Force Military Medical University, China
Hypertension, Portal
Carvedilol and Alverine in Portal Hypertension
Brief summaries of CZXH-PH-ALV-2403 The goal of this clinical trial is to learn if the combination of alverine and carvedilol works to treat portal hypertension in adult patients with liver cirrhosis.
- Trial name
- NCT06696248
- Testing
- Carvedilol and alverine
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Hepatocellular Carcinoma, Hepatitis C Virus Infection
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C Virus Infection, Liver Cirrhosis, Interferon Treatment
- Trial name
- NCT00273247
- Testing
- Interferon alpha-2b
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Milan